Migraine market grab by CGRP inhibitors: Data Byte

Amgen’s first-mover advantage among CGRP therapies for migraine appears to have been overcome, as both Eli Lilly’s Emgality and AbbVie’s Ubrelvy surpassed Amgen’s Aimovig in first quarter sales.

FDA approved Aimovig erenumab-aooe from  Amgen Inc. (NASDAQ:AMGN) as the first CGRP inhibitor to treat migraine in May 2018. Since then, five others have entered the market and several of them are taking off. ...